Detalles de la búsqueda
1.
Methodology for computing the burden of disease of adverse events following immunization.
Pharmacoepidemiol Drug Saf;
27(7): 724-730, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29575242
2.
Post-marketing monitoring of intussusception after rotavirus vaccination in Japan.
Pharmacoepidemiol Drug Saf;
24(7): 765-70, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26013569
3.
Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm.
Pharmacoepidemiol Drug Saf;
23(2): 178-85, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24038719
4.
The upper bound to the Relative Reporting Ratio-a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection.
Pharmacoepidemiol Drug Saf;
23(8): 787-94, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24395594
5.
Signal detection based on time-to-onset: extending a new method from spontaneous reports to observational studies.
Pharmacoepidemiol Drug Saf;
23(8): 849-58, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24946233
6.
The Brighton collaboration standardized module for vaccine benefit-risk assessment.
Vaccine;
42(4): 972-986, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38135642
7.
Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization.
Pharmacoepidemiol Drug Saf;
22(5): 477-87, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23255430
8.
Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
Drug Saf;
46(4): 327-333, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37040044
9.
Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study.
Pharmacoepidemiol Drug Saf;
21(6): 603-10, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22383219
10.
Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines.
Pharmacoepidemiol Drug Saf;
25(2): 215-22, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26602179
11.
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.
Drug Saf;
43(11): 1089-1104, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914292
12.
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).
Drug Saf;
43(11): 1105-1120, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32918682
13.
ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling.
Vaccine;
38 Suppl 2: B65-B75, 2020 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677947
14.
ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination.
Vaccine;
38 Suppl 2: B38-B46, 2020 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677946
15.
ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases.
Vaccine;
38 Suppl 2: B76-B83, 2020 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677951
16.
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
Vaccine;
38 Suppl 2: B1-B7, 2020 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31677952
17.
Tree-based scan statistic - Application in manufacturing-related safety signal detection.
Vaccine;
37(1): 49-55, 2019 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30470642
18.
Estimation of vaccination coverage from electronic healthcare records; methods performance evaluation - A contribution of the ADVANCE-project.
PLoS One;
14(9): e0222296, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31532806
19.
Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe.
Vaccine;
37(25): 3278-3289, 2019 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31072735
20.
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Vaccine;
37(23): 3006-3021, 2019 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31031030